Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - The overall growth for the quarter was reported as negative 1%, which does not accurately reflect the underlying performance of the company [2] - Core growth, excluding certain factors like cell therapy, was positive at 1% [1][2] Market Performance - Large pharma, which constitutes 30% of the company's revenues, showed strong performance with double-digit growth [3] - Concerns regarding tariffs had previously led to worries about large pharma potentially reducing orders, but this did not materialize, resulting in a positive outcome for the quarter [3]